文献速递神经儿科影像MR

复发性髓母细胞瘤颅脑脊髓MRI疗效评估

Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI.
PubMed 文献 · Eur J Radiol · 2026-07-09

本研究回顾性分析40例复发性经放疗髓母细胞瘤患者接受MEMMAT治疗的颅脑脊髓MRI,对T1增强和DWI病灶手动分割并量化数量与体积。完全缓解、部分缓解和疾病稳定患者病灶数量与体积呈下降趋势,疾病进展患者则明显上升。基线肿瘤体积≥5.5ml者总生存期显著更短,联合颅内及脊髓T1增强与颅内DWI可改善疗效评估。

要点

  • 联合颅内及脊髓T1增强与颅内DWI评估优于单一序列,单一序列可致23%患者误分类
  • 基线肿瘤体积≥5.5ml的患者总生存期显著更短,阅片时应关注肿瘤负荷
  • T1增强与DWI病灶数量及体积一致性有限,报告中建议分别描述两序列所见

核心结论

  • 联合颅内及脊髓T1增强与颅内DWI评估可改善复发性髓母细胞瘤疗效评价。
  • 基线肿瘤负荷较高可能与疾病进展相关,但关联处于临界统计学意义,需更大队列验证。
  • 基线病灶体积≥5.5ml的患者总生存期显著更短,无进展生存期关联未达统计学意义。

研究设计与样本

  • 回顾性研究,纳入40例复发性经放疗髓母细胞瘤患者,均来自MEMMAT试验。
  • MEMMAT试验入组时间为2014年4月1日至2021年3月31日。
  • 对基线及随访最佳疗效时的T1增强和DWI图像进行室管膜、软脑膜及局部复发灶手动分割。
  • 采用Bland-Altman分析和组内相关系数评估序列间一致性,logistic回归分析基线肿瘤负荷与疾病进展的关联。

关键影像表现/征象

  • 完全缓解患者(6/40)T1增强病灶数量月均下降12.7%,体积月均下降12.9%。
  • 部分缓解患者(9/40)病灶数量月均下降10.3%,体积月均下降13.0%。
  • 疾病稳定患者(5/40)病灶数量月均下降0.8%,体积月均下降2.3%,变化幅度很小。
  • 疾病进展患者(16/40)病灶数量月均增加33.7%,体积月均增加56.2%。

诊断标准与关键数值

  • T1增强与DWI的病灶数量组内相关系数为0.35,体积组内相关系数为0.47,一致性有限。
  • 仅用单一序列评估时23%的患者被错误分类。
  • logistic回归显示基线肿瘤体积预测疾病进展的比值比为1.18,P=0.08。
  • logistic回归显示基线病灶数量预测疾病进展的比值比为1.05,P=0.075。
  • 基线病灶体积≥5.5ml的患者总生存期显著更短,log-rank检验P=0.003。

临床应用与阅片要点

  • 阅片时应同时评估颅内和脊髓T1增强序列及颅内DWI序列,避免仅依赖单一序列下结论。
  • 报告基线肿瘤体积对预后有提示意义,特别是5.5ml这一界值可用于风险分层参考。
  • 随访时关注病灶数量与体积的月均变化趋势,疾病进展时两者均可明显上升。

局限性

  • 本研究为回顾性设计,病灶手动分割存在潜在操作者依赖性。
  • 基线肿瘤负荷与疾病进展的关联处于临界统计学意义,需更大样本队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: To evaluate whether quantitative craniospinal MRI assessment of baseline tumor burden provides prognostic value in patients with recurrent, previously irradiated medulloblastoma undergoing MEMMAT (Metronomic Antiangiogenic) therapy.

METHODS: We analyzed craniospinal MRI of 40 patients with recurrent, previously irradiated medulloblastoma enrolled in the MEMMAT trial (April 1, 2014, and March 31, 2021). Ependymal, leptomeningeal, and local relapse lesions were retrospectively manually segmented on T1-contrast-enhanced (T1CE) and diffusion-weighted imaging (DWI) at baseline and follow-up (best response). Lesion count and volume were quantified. Bland-Altman analyses and intraclass correlation coefficients (ICC) assessed inter-sequence agreement., logistic regression evaluated associations between baseline tumor burden and progressive disease.

RESULTS: Patients achieving Complete Response (n = 6/40) showed mean monthly decreases of - 12.7% in T1CE lesion count and - 12.9% in volume. Partial Response patients (n = 9/40) showed similar declines (-10.3% and - 13.0%). Stable Disease patients (n = 5/40) demonstrated minimal decreases (-0.8% and - 2.3%). Progressive Disease patients (n = 16/40) showed increases of 33.7% in lesion count and 56.2% in volume. Logistic regression indicated trends toward higher baseline tumor burden predicting PD (volume OR 1.18, p = 0.08; lesion count OR 1.05, p = 0.075). Agreement between T1CE and DWI was limited (ICC 0.35 for lesion count, 0.47 for volume), with 23% of patients misclassified using either modality alone. Survival analyses demonstrated significantly shorter overall survival in patients with baseline lesion volumes ≥ 5.5 ml (log-rank p = 0.003), while a similar association for progression-free survival did not reach statistical significance (p = 0.053).

CONCLUSIONS: Combined intracranial and intraspinal T1CE and intracranial DWI assessment improves response evaluation. Exploratory analyses suggested that higher baseline tumor burden may be associated with progression, although the observed associations were of borderline statistical significance and require validation in larger cohorts.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hennenberg, Hofer, Nemeth, et al. Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI. Eur J Radiol. 2026. PMID: 42437539. doi:10.1016/j.ejrad.2026.113056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。